2180 A Molecular Study of the Saudi Glioma Cohort: Genome-Wide Copy Number Screening, Retrospective Analysis of Clinicopathological Features, and Long-Term Clinical Outcomes

View at publisher Summarise with VIRAT
Authors: Maeen Al Damouni, Abdulrahman Alnweji, Faisal Abdulhameed Farrash
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Diffuse gliomas represent the most aggressive and fatal primary brain tumors worldwide. Although IDH mutation and MGMT promoter methylation are established prognostic markers, comprehensive data on copy number alterations and their impact on long-term outcomes in Middle Eastern populations are scarce. METHODS: We retrospectively analyzed 127 adult patients who underwent resection for WHO 2021–classified diffuse gliomas (grades II–IV) at a tertiary Saudi center from 2010–2023. Clinical, radiographic, and histopathological data—including IDH, 1p/19q codeletion, and MGMT status—were collected. Tumor DNA was subjected to high-resolution copy number screening and targeted sequencing of 50 glioma-relevant genes. Kaplan–Meier survival curves and multivariable Cox regression identified predictors of progression-free survival (PFS) and overall survival (OS). RESULTS: The cohort (mean age 45.2 ± 13.1 years; 58% male) included 35 grade II, 27 grade III, and 65 grade IV gliomas. IDH1 R132H mutations (32%), TP53 mutations (24%), and MGMT methylation (38%) mirrored global trends. Copy number gains in EGFR (42%) and deletions in CDKN2A/B (28%) were frequent. Notably, FGFR3-TACC3 fusions—identified in 10 cases (7.9%)—were previously unreported in this region. Over a median follow-up of 34 months, 62% recurred. FGFR3-TACC3–positive tumors exhibited significantly shorter PFS (median 11 vs. 19 months; HR 2.8; 95% CI 1.5–5.0; p = 0.003) and lower 3-year OS (24% vs. 49%; p = 0.01), independent of grade and MGMT status. CONCLUSIONS: This Saudi glioma series confirms established molecular alterations and uncovers FGFR3-TACC3 fusions as a novel adverse prognostic marker. Integrating screening for FGFR3-TACC3 may refine risk stratification and guide targeted therapeutic approaches. Prospective validation in larger cohorts is warranted.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Cancer Genomics and Diagnostics Acute Myeloid Leukemia Research

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
296–296
Publication date
26 March 2026
Language
EN